Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medtronic plc (NYSE: MDT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, giving investors and analysts a detailed view of its financial condition, capital structure, governance, and material events. As an issuer with ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, Medtronic files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A, and specialized forms such as Form 25 for the removal from listing of specific debt securities.
Medtronic’s Form 8-K filings cover topics such as quarterly financial results, debt offerings, redemptions of senior notes, amendments to its Memorandum and Articles of Association, changes in board composition and executive roles, and other material definitive agreements. For example, recent 8-Ks describe euro-denominated senior notes due 2030 and 2045, their guarantees by Medtronic plc and affiliates, and the use of proceeds to repay existing notes. Other current reports document National Coverage Determinations, financial guidance updates, and dividend-related actions referenced in company news releases.
The company’s proxy statements (DEF 14A) outline its corporate governance structure, director elections, executive compensation programs, and shareholder proposals, including amendments to Articles of Association and capital reduction measures under Irish law. Form 25 filings relate to the delisting of specific classes of guaranteed senior notes once they are redeemed or otherwise withdrawn from the exchange, and do not affect the listing of MDT ordinary shares.
On this page, Stock Titan pairs Medtronic’s filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand items such as new debt issuances, changes in capital structure, or governance amendments. You can review 10-K and 10-Q reports for segment performance and risk disclosures, scan 8-Ks for notable events, and monitor registration statements and S-1 filings, such as the proposed IPO of the MiniMed diabetes business, to follow Medtronic’s strategic and financial decisions over time.
Medtronic plc filed an 8-K disclosing a Sixth Supplemental Indenture dated September 29, 2025 among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., with Computershare Trust Company, N.A. as successor trustee and U.S. Bank Europe DAC, UK Branch as paying agent. The filing includes the forms of the 2030 Notes and the 2045 Notes, and attaches legal opinions from U.S., Irish and Luxembourg counsel plus consents from each counsel and an internal opinion by an Assistant Secretary. The submission also references an embedded Cover Page Interactive Data File and is signed by Thierry Pi e9ton, Executive Vice President and Chief Financial Officer.
Medtronic plc filed an 8-K disclosing an Underwriting Agreement dated September 15, 2025 among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., with Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC named as the representatives of the several underwriters. The filing also notes an embedded Cover Page Interactive Data File with the Inline XBRL document. The filing is signed on September 16, 2025 by Thierry Piéton, Executive Vice President and Chief Financial Officer.
The notice identifies the existence and date of the underwriting arrangement and the lead underwriters but does not disclose transaction size, terms, or intended use of proceeds.
Medtronic plc filed an 8-K disclosing an Underwriting Agreement dated September 15, 2025 among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., with Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC named as the representatives of the several underwriters. The filing also notes an embedded Cover Page Interactive Data File with the Inline XBRL document. The filing is signed on September 16, 2025 by Thierry Piéton, Executive Vice President and Chief Financial Officer.
The notice identifies the existence and date of the underwriting arrangement and the lead underwriters but does not disclose transaction size, terms, or intended use of proceeds.
Medtronic plc is offering debt securities, including $750,000,000 aggregate principal amount of 4.200% senior notes due October 15, 2045. The prospectus supplement states certain pricing rows showing prices to investors near 99.97% with underwriting discounts of 0.35% and 0.65%, producing proceeds to Medtronic, Inc. around 99.62% and 99.25% respectively. As of July 25, 2025, the company reported approximately $28.6 billion of debt outstanding, including $27.8 billion aggregate principal of senior debt of Medtronic plc, Medtronic Luxco and Medtronic, Inc.
The supplement explains that Medtronic Luxco and Medtronic, Inc. are wholly‑owned indirect subsidiaries of Medtronic plc and that notes issued by Medtronic, Inc. will be fully and unconditionally guaranteed on a joint and several basis by Medtronic plc and Medtronic Luxco. The indenture does not prohibit additional unsecured indebtedness or significant secured indebtedness and certain tax, withholding and investor eligibility provisions are described. Financial statements for Luxco and Medtronic, Inc. are not separately included; Medtronic plc provides alternative summarized disclosure under Regulation S‑X.
Medtronic insider stock sales reported. The reporting person, EVP & President Cardiovascular Harry "Skip" Kiil, sold a total of 8,605 ordinary shares in two transactions on 09/03/2025 at prices of about $91.58 and $91.59. After these dispositions the reporting person beneficially owns 35,615 ordinary shares, held directly. The Form 4 was submitted to disclose these non-derivative sales and the change in beneficial ownership.
Medtronic (MDT) Form 144 summary: The filing notifies an intended sale of 8,605 shares of Medtronic common stock held at Fidelity Brokerage Services, with an aggregate market value of $788,048.74. The shares were acquired on 08/01/2025 through restricted stock vesting from the issuer as compensation and the filer lists an approximate sale date of 09/03/2025 on the NYSE. The filing states there were no other securities sold by the same person in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Medtronic (MDT) reported first-quarter fiscal 2026 operating details showing continued product-driven revenue growth across core portfolios and ongoing corporate actions. The company announced in May 2025 its intent to separate the Diabetes Operating Unit into a standalone public company, expected within 18 months. Cardiovascular net sales were up, with Cardiac Rhythm & Heart Failure rising 12%, Structural Heart & Aortic up 9%, and Coronary & Peripheral Vascular up 5%. Medical Surgical net sales were $2.1 billion, up 4% year-over-year. Research and development expense was $726 million versus $676 million a year earlier, and selling, general, and administrative expense was $2.8 billion versus $2.7 billion. The company recognized a $90 million fair-value loss on its Mozarc investment and recorded restructuring charges of $67 million. Deferred revenue was $442 million. Total debt was $28.6 billion while liquidity included $1.3 billion cash and $6.8 billion of current investments. Accrued litigation was approximately $0.2 billion; legal and tax matters remain disclosed as potentially material.
William R. Jellison, a director of Medtronic plc (MDT), reported two open-market purchases of ordinary shares. He acquired 2,500 shares on 08/22/2025 at $92.73 per share and 2,500 shares on 08/25/2025 at $92.37 per share, bringing his reported direct beneficial ownership to 5,000 shares. The filing notes the shares are held in a joint account with his spouse. The Form 4 was executed by an attorney-in-fact on 08/25/2025. No derivative transactions or dispositions are reported in this filing.
Medtronic plc (MDT) outlines FY25 operational and governance highlights in its 2025 Definitive Proxy Statement. The company reported $7.0 billion in cash flow from operations (up 4%) and $5.2 billion in free cash flow, representing a 73% conversion from non-GAAP net earnings. Medtronic returned $6.3 billion to shareholders via $3.6 billion in dividends and $2.7 billion in net share repurchases and announced a dividend increase for the 48th consecutive year. The company invested $2.7 billion in R&D, advanced an innovation pipeline with ~170 active clinical trials and ~130 regulatory approvals, and launched multiple products across portfolios. Medtronic reduced Class 1 and 2 recalls by 33% and announced intent to separate the Diabetes segment via IPO/split within 18 months.
Michael Marinaro, Executive Vice President, President MedSurg and Americas at Medtronic plc (MDT), reported a disposition of 1,052 ordinary shares on 08/20/2025. The shares were disposed at a reported price of $93.22 and the filing states this transaction represents shares withheld for payment of taxes upon vesting of previously reported restricted stock units. After the transaction, Marinaro beneficially owned 51,939 ordinary shares. The Form 4 is signed by an attorney-in-fact, Patricia Walesiewicz, dated 08/21/2025. The filing discloses only the withholding tax disposition and current beneficial ownership.
Medtronic director filing reports no beneficial ownership. The Form 3 shows William R. Jellison as a director of Medtronic plc (MDT) and indicates he does not beneficially own any ordinary shares or derivative securities. The filing was submitted as an initial statement and was signed by an attorney-in-fact. No transactions, holdings, or indirect ownership interests are reported.
Medtronic director filing reports no beneficial ownership. The Form 3 shows William R. Jellison as a director of Medtronic plc (MDT) and indicates he does not beneficially own any ordinary shares or derivative securities. The filing was submitted as an initial statement and was signed by an attorney-in-fact. No transactions, holdings, or indirect ownership interests are reported.